TR200000755T2 - Karşıt olma-karşı gelme bozukluğunun tedavisi. - Google Patents

Karşıt olma-karşı gelme bozukluğunun tedavisi.

Info

Publication number
TR200000755T2
TR200000755T2 TR2000/00755T TR200000755T TR200000755T2 TR 200000755 T2 TR200000755 T2 TR 200000755T2 TR 2000/00755 T TR2000/00755 T TR 2000/00755T TR 200000755 T TR200000755 T TR 200000755T TR 200000755 T2 TR200000755 T2 TR 200000755T2
Authority
TR
Turkey
Prior art keywords
treatment
disorder
oppositional disorder
oppositional
antitussive
Prior art date
Application number
TR2000/00755T
Other languages
English (en)
Inventor
Harrison Heiligenstein John
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of TR200000755T2 publication Critical patent/TR200000755T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Norepinefrin yeniden yükselme inhibitörleri karsit olma, karsi gelme bozuklugunun tedavi edilmesi için kullanilmaktadir.
TR2000/00755T 1997-09-23 1998-09-01 Karşıt olma-karşı gelme bozukluğunun tedavisi. TR200000755T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5962997P 1997-09-23 1997-09-23

Publications (1)

Publication Number Publication Date
TR200000755T2 true TR200000755T2 (tr) 2000-09-21

Family

ID=22024203

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/00755T TR200000755T2 (tr) 1997-09-23 1998-09-01 Karşıt olma-karşı gelme bozukluğunun tedavisi.

Country Status (17)

Country Link
US (1) US6028070A (tr)
EP (1) EP0919236A1 (tr)
JP (1) JP2001517627A (tr)
KR (1) KR20010024218A (tr)
CN (1) CN1146412C (tr)
AU (1) AU740109B2 (tr)
BR (1) BR9812357A (tr)
CA (1) CA2304115A1 (tr)
EA (1) EA002689B1 (tr)
HU (1) HUP0003591A3 (tr)
IL (1) IL134716A0 (tr)
NO (1) NO20001458L (tr)
NZ (1) NZ502810A (tr)
PL (1) PL339426A1 (tr)
TR (1) TR200000755T2 (tr)
UA (1) UA56257C2 (tr)
WO (1) WO1999015176A1 (tr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1301164A (zh) 1998-04-09 2001-06-27 法玛西雅厄普约翰美国公司 神经病症的新疗法
US6500827B2 (en) * 1998-05-08 2002-12-31 Pharmacia & Upjohn Company Drug combinations
EP1459749B1 (en) * 1999-07-01 2005-10-05 Pharmacia & Upjohn Company LLC (S,S)-reboxetine for treating incontinence
EA011094B1 (ru) 1999-07-01 2008-12-30 Фармация Энд Апджон Компани Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
US6387403B1 (en) * 1999-09-15 2002-05-14 Alza Corporation Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
WO2001066101A2 (en) * 2000-03-07 2001-09-13 Eli Lilly And Company Treatment of psoriasis
WO2002078629A2 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US6613763B2 (en) * 2001-04-20 2003-09-02 Mgi Applied Genomics Use of molindone to treat oppositional defiant disorder and conduct disorder
US6602911B2 (en) * 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
EP1482921A1 (en) * 2002-02-12 2004-12-08 Cypress Bioscience, Inc. Methods of treating attention deficit/hyperactivity disorder (adhd)
EP1485078B1 (en) * 2002-03-15 2012-09-26 Cypress Bioscience, Inc. Milnacipran for the treatment of irritable bowel syndrome
EP1494664A2 (en) * 2002-04-18 2005-01-12 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
WO2003090743A1 (en) * 2002-04-24 2003-11-06 Cypress Bioscience, Inc. Prevention and treatment of functional somatic disorders, including stress-related disorders
WO2003092649A2 (en) * 2002-04-29 2003-11-13 Alza Corporation Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation
NZ537023A (en) * 2002-06-17 2006-09-29 Pharmacia Italia Spa Pharmaceutical salts of reboxetine
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
ES2310715T3 (es) * 2003-02-14 2009-01-16 Pierre Fabre Medicament Uso del enantiomero (1s,2r) del milnacipran para la preparacion de un medicamento.
FR2851163B1 (fr) * 2003-02-14 2007-04-27 Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
ATE526954T1 (de) * 2003-07-28 2011-10-15 Leslie Joe Dunaway Atomoxetin zur behandlung von allergischer rhinitis und asthma
ES2390879T3 (es) * 2003-12-31 2012-11-19 Actavis Group Ptc Ehf. Formulaciones de atomoxetina
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
US7994220B2 (en) * 2005-09-28 2011-08-09 Cypress Bioscience, Inc. Milnacipran for the long-term treatment of fibromyalgia syndrome
US20080081067A1 (en) * 2006-10-03 2008-04-03 Gupta Manishkumar Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
WO2011057176A1 (en) 2009-11-06 2011-05-12 Forest Laboratories Holding Limited Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
DK0537915T3 (da) * 1991-09-27 1995-11-27 Lilly Co Eli N-alkyl-3-phenyl-3-(2-alkylthiophenoxy)propylaminer som inhibitorer for epinephrin
ZA93694B (en) * 1993-02-01 1993-06-03 Lilly Co Eli Pharmaceutical treatments.
CA2134038C (en) * 1994-06-16 1997-06-03 David Taiwai Wong Potentiation of drug response
ZA958725B (en) * 1994-10-20 1997-04-16 Lilly Co Eli Treatment of disorders with duloxetine
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
AU709704B2 (en) * 1995-07-24 1999-09-02 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
US5696168A (en) * 1995-07-24 1997-12-09 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
EA200000349A1 (ru) 2000-10-30
AU9128298A (en) 1999-04-12
WO1999015176A1 (en) 1999-04-01
BR9812357A (pt) 2000-09-12
PL339426A1 (en) 2000-12-18
CN1270520A (zh) 2000-10-18
HUP0003591A2 (hu) 2002-01-28
IL134716A0 (en) 2001-04-30
AU740109B2 (en) 2001-11-01
NZ502810A (en) 2002-03-01
NO20001458D0 (no) 2000-03-21
NO20001458L (no) 2000-03-21
JP2001517627A (ja) 2001-10-09
KR20010024218A (ko) 2001-03-26
UA56257C2 (uk) 2003-05-15
EP0919236A1 (en) 1999-06-02
EA002689B1 (ru) 2002-08-29
CA2304115A1 (en) 1999-04-01
US6028070A (en) 2000-02-22
HUP0003591A3 (en) 2002-02-28
CN1146412C (zh) 2004-04-21

Similar Documents

Publication Publication Date Title
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
EA200000351A1 (ru) Лечение кондуктивных нарушений
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
MY151032A (en) Treatment of tnf? related disorders
ATE279921T1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
AU1718400A (en) Method for treating pain
UA43385C2 (uk) Спосіб лікування синдрому дефіциту уваги/гіперактивності
FR12C0052I2 (fr) Utilisation de dapoxetine, un inhibiteur selectif de recaptage de serotonine a action rapide, pour traiter un dysfonctionnement sexuel
AU3831301A (en) Method for treating ocular pain
ATE214272T1 (de) Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz
MY136367A (en) Treatment of cognitive failure
EA199800152A1 (ru) Лечение синдрома дефицита внимания/гиперактивности
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
EA199800866A1 (ru) Способ снятия боли
EA200200948A1 (ru) Лечение псориаза
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
UY26265A1 (es) Compuestos calciolíticos
BR0115301A (pt) Uso de um inibidor seletivo da recaptação de norepinefrina
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
EA199800819A1 (ru) Способ лечения биполярного расстройства
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
IS6017A (is) Aðferð til meðhöndlunar á höfuðverk
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
PT1017377E (pt) Utilizacao de 2-aminotetralinas 6,7-substituidas para o tratamento de condicoes inflamatorias mediadas por citoquina